Chest
Volume 130, Issue 4, Supplement, October 2006, Page 254S
Journal home page for Chest

Poster Presentations
PHARMACOKINETIC INTERACTION BETWEEN TADALAFIL AND BOSENTAN IN HEALTHY MALE SUBJECTS

https://doi.org/10.1378/chest.130.4_MeetingAbstracts.254S-bGet rights and content

Section snippets

Abstract

PURPOSE: Tadalafil is an oral phosphodiesterase type 5 (PDE5) inhibitor approved for the treatment of erectile dysfunction and under investigation for the once-daily treatment of pulmonary arterial hypertension (PAH). Since bosentan is an oral, dual endothelin receptor antagonist indicated in the treatment of patients with PAH, this study determined whether pharmacokinetic interactions exist between tadalafil and bosentan.

METHODS: This was an open-label, randomized, three-period crossover

References (0)

Cited by (0)

View full text